Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): A multicentre, randomised study

BMC Pulmonary Medicine

Volumn 14, Issue 1, 2014, Pages

  Singh, Dave ^a   Jones, Paul W ^b   Bateman, Eric D ^c   Korn, Stephanie ^d   Serra, Cristina ^e   Molins, Eduard ^f   Caracta, Cynthia ^g   Gil, Garcia ^f   Leselbaum, Anne ^e  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e Almirall RandD Centre ^*  (Spain)

^f ASTRAZENECA   (United Kingdom)

^g FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Aclidinium bromide formoterol fumarate; Chronic obstructive pulmonary disease; Fixed dose combination

Indexed keywords

ACLIDINIUM BROMIDE; ACLIDINIUM BROMIDE PLUS FORMOTEROL FUMARATE; FORMOTEROL FUMARATE; PLACEBO; DRUG COMBINATION; TROPANE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AIRWAY OBSTRUCTION; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD PRESSURE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG USE; DRY POWDER INHALER; DYSPNEA; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEART FAILURE; HUMAN; HYPERTENSION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OROPHARYNX PAIN; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PNEUMONIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE ASSESSMENT; RHINITIS; RHINOPHARYNGITIS; SINUSITIS; SPIROMETRY; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TRANSITION DYSPNOEA INDEX; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; AGED; AGONISTS; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DRUG COMBINATION; MIDDLE AGED; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; VITAL CAPACITY;

AGED; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FORMOTEROL FUMARATE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TROPANES; VITAL CAPACITY;

EID: 84921459850     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-14-178     Document Type: Article

References (33)

1. Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 2014. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf
2. Cazzola M, Calzetta L, Matera MG: beta(2) -adrenoceptor agonists: current and future direction. Br J Pharmacol 2011, 163:4-17. 10.1111/j.1476-5381.2011.01216.x
3. Cazzola M, Page CP, Calzetta L, Matera MG: Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012, 64:450-504. 10.1124/pr.111.004580
4. IMS Health LS: IMS Data 5/2011-4/2012. Danbury, CT, US: IMS Health Incorporated; 2012.
5. Tashkin DP, Ferguson GT: Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res 2013, 14:49. 10.1186/1465-9921-14-49
6. Rudolf M, Tashkin DP: Bronchodilators - future role in the management of chronic obstructive pulmonary disease. Eur Respir Dis 2012, 8:108-115.
7. Cazzola M, Rogliani P, Matera MG: Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2013, 14:775-781. 10.1517/14656566.2013.776539
8. Partridge MR, Karlsson N, Small IR: Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009, 25:2043-2048. 10.1185/03007990903103006
9. Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2010. http://www.goldcopd.org/Guidelines/guideline-2010-gold-report.html
10. Leidy NK, Wilcox TK, Jones PW, Murray L, Winnette R, Howard K, Petrillo J, Powers J, Sethi S: Development of the EXAcerbations of Chronic obstructive pulmonary disease Tool (EXACT): a patient-reported outcome (PRO) measure. Value Health 2010, 13:965-975. 10.1111/j.1524-4733.2010.00772.x
11. Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S: Standardizing measurement of chronic obstructive pulmonary disease exacerbations: reliability and validity of a patient-reported diary. Am J Respir Crit Care Med 2011, 183:323-329. 10.1164/rccm.201005-0762OC
12. Leidy NK, Murray LT: Patient-reported outcome (PRO) measures for clinical trials of COPD: the EXACT and E-RS. COPD 2013, 10:393-398. 10.3109/15412555.2013.795423
13. Leidy NK, Murray LT, Jones P, Sethi S: Performance of the EXAcerbations of Chronic pulmonary disease Tool patient-reported outcome measure in three clinical trials of chronic obstructive pulmonary disease. Ann Am Thorac Soc 2014, 11:316-325. 10.1513/AnnalsATS.201309-305OC
14. European Medicines Agency: Guideline on Clinical Development of Fixed Combination Medicinal Products (CHMP/EWP/240/95) Rev.1. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003686.pdf
15. US Food and Drug Administration: Code of Federal Regulations. Title 21. Section 300.50. Fixed-Combination Prescription Drugs for Humans. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=300.50
16. Benhamou D, Cuvelier A, Muir JF, Leclerc V, Le Gros V, Kottakis J, Bourdeix I: Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). Respir Med 2001, 95:817-821. 10.1053/rmed.2001.1161
17. Tashkin DP, Fabbri LM: Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res 2010, 11:149. 10.1186/1465-9921-11-149
18. Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF, ACCORD I study investigators: Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012, 9:90-101. 10.3109/15412555.2012.661492
19. Jones PW, Singh D, Bateman ED, Agusti A, Lamarca R, de Miquel G, Segarra R, Caracta C, Garcia Gil E: Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 2012, 40:830-836. 10.1183/09031936.00225511
20. Aalbers R, Maleki-Yazdi MR, Hamilton A, Waitere-Wijker S, Pivovarova A, Schmidt O, Bjermer L: Dose-Finding Study for Tiotropium and Olodaterol When Administered in Combination via the Respimat® Inhaler in Patients with COPD. Vienna, Austria: Poster presented at the European Respiratory Society Annual Congress; 2012.
21. Bateman ED, Ferguson GT, Barnes N, Gallagher N, Green Y, Henley M, Banerji D: Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013, 42:1484-1494. 10.1183/09031936.00200212
22. Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A: Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med 2013, 107:1538-1546. 10.1016/j.rmed.2013.06.001
23. Maltais F, Beck E, Webster D, Maleki-Yazdi MR, Seibt J-V, Arnoux A, Hamilton A: Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients [abstract]. Eur Respir J 2010, 36:1014s.
24. Reisner C, Fogarty C, Spangenthal S, Dunn L, Kerwin EM, Quinn D, Seale JP, Thomas M, St Rose E, Orevillo C: Novel combination of glycopyrrolate and formoterol MDI (GFF-MDI) provides superior bronchodilation compared to its components administered alone, tiotropium DPI, and formoterol DPI in a randomized, double-blind, placebo-controlled Phase 2b study in patients with COPD [abstract]. Am J Resp Crit Care Med 2011, 183:A6435.
25. Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA: Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med 2014, 189:250-255. 10.1164/rccm.201310-1863PP
26. Donohue JF: Minimal clinically important differences in COPD lung function. COPD 2005, 2:111-124. 10.1081/COPD-200053377
27. Kaptchuk TJ, Friedlander E, Kelley JM, Sanchez MN, Kokkotou E, Singer JP, Kowalczykowski M, Miller FG, Kirsch I, Lembo AJ: Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One 2010, 5:e15591. 10.1371/journal.pone.0015591
28. 1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res 2011, 12:40. 10.1186/1465-9921-12-40
29. Rabe KF, Fabbri LM, Vogelmeier C, Kogler H, Schmidt H, Beeh KM, Glaab T: Seasonal distribution of COPD exacerbations in the prevention of exacerbations with tiotropium in COPD trial. Chest 2013, 143:711-719.
30. Kessler R, Partridge MR, Miravitlles M, Cazzola M, Vogelmeier C, Leynaud D, Ostinelli J: Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011, 37:264-272. 10.1183/09031936.00051110
31. Kew KM, Mavergames C, Walters JA: Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013, 10:CD010177.
32. Jansat JM, Lamarca R, Garcia Gil E, Ferrer P: Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. Int J Clin Pharmacol Ther 2009, 47:460-468. 10.5414/CPP47460
33. Sentellas S, Ramos I, Albertí J, Salvà M, Antón F, Miralpeix M, Beleta J, Gavaldà A: Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci 2010, 39:283-290. 10.1016/j.ejps.2010.01.004